Ryan Gentzler

University of Virginia

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (6)

Michelle A. Rudek

Johns Hopkins University

UNITED STATES

View details

Mitch Phelps

Ohio State University

UNITED STATES

View details

Oliver Hampton

Chief Data Officer

Southwest Research Institute

UNITED STATES

View details

Susanne Arnold

University of Kentucky

UNITED STATES

View details

Patrick Dillon

Assistant Professor

University of Virginia

UNITED STATES

View details

Todd Stukenberg

Professor

University of Virginia Hospital

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ryan Gentzler

Research Interests

Explore related searches

Contact this professor

Articles (10)

Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399

Phase I/II Trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced Non–Small Cell Lung Cancer: Hoosier Cancer Research Network LUN13-175

A Brief Report of a Phase II trial Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer

Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibition in Combination With Chemotherapy: A Brief Report

A Phase II Trial of Atezolizumab Plus Carboplatin Plus Pemetrexed Plus Bevacizumab in the Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer: Big Ten Cancer Research Consortium (BTCRC)- LUN 17-139

Association of sarcopenia with survival in advanced NSCLC patients receiving concurrent immunotherapy and chemotherapy

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

Replicative Instability Drives Cancer Progression

A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)

Collaborators (6)

Michelle A. Rudek

Mitch Phelps

Oliver Hampton

Susanne Arnold

Patrick Dillon

Todd Stukenberg

Make your next move.